Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brigitte C Widemann

Showing results (161-170 of 203) with videos related to

Pageof 21
Sort By:
Clinical Trials (London, England)|October 25, 2023
Development and pilot validation of a novel disfigurement severity scale for plexiform neurofibromas in children with neurofibromatosis type 1Liny John, Gurbani Singh, Eva Dombi, et al.
American Journal of Human Genetics|February 27, 2019
Pharmacodynamic Study of Miransertib in Individuals with Proteus SyndromeKim M Keppler-Noreuil, Julie C Sapp, Marjorie J Lindhurst, et al.
Neuro-Oncology|February 7, 2014
Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromasBrigitte C Widemann, Eva Dombi, Andrea Gillespie, et al.
Neuro-Oncology|February 6, 2019
Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromasAlexander Pemov, Nancy F Hansen, Sivasish Sindiri, et al.
Neuro-Oncology|April 28, 2023
Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromasAndrea M Gross, Eva Dombi, Pamela L Wolters, et al.
Neurology|November 20, 2013
Recommendations for imaging tumor response in neurofibromatosis clinical trialsEva Dombi, Simone L Ardern-Holmes, Dusica Babovic-Vuksanovic, et al.
Plos Medicine|August 31, 2021
Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional studyJeffrey J Szymanski, R Taylor Sundby, Paul A Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2021
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform NeurofibromasBrian D Weiss, Pamela L Wolters, Scott R Plotkin, et al.
Molecular Pharmacology|June 9, 2019
Severe Hepatotoxicity of Mithramycin Therapy Caused by Altered Expression of Hepatocellular Bile TransportersTristan M Sissung, Phoebe A Huang, Ralph J Hauke, et al.
Sarcoma|November 16, 2017
SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath TumorsChristine S Higham, Seth M Steinberg, Eva Dombi, et al.
Pageof 21

Showing results (161-170 of 203) with videos related to

Sort By:
Pageof 21
Clinical Trials (London, England)|October 25, 2023
Development and pilot validation of a novel disfigurement severity scale for plexiform neurofibromas in children with neurofibromatosis type 1Liny John, Gurbani Singh, Eva Dombi, et al.
American Journal of Human Genetics|February 27, 2019
Pharmacodynamic Study of Miransertib in Individuals with Proteus SyndromeKim M Keppler-Noreuil, Julie C Sapp, Marjorie J Lindhurst, et al.
Neuro-Oncology|February 7, 2014
Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromasBrigitte C Widemann, Eva Dombi, Andrea Gillespie, et al.
Neuro-Oncology|February 6, 2019
Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromasAlexander Pemov, Nancy F Hansen, Sivasish Sindiri, et al.
Neuro-Oncology|April 28, 2023
Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromasAndrea M Gross, Eva Dombi, Pamela L Wolters, et al.
Neurology|November 20, 2013
Recommendations for imaging tumor response in neurofibromatosis clinical trialsEva Dombi, Simone L Ardern-Holmes, Dusica Babovic-Vuksanovic, et al.
Plos Medicine|August 31, 2021
Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional studyJeffrey J Szymanski, R Taylor Sundby, Paul A Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2021
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform NeurofibromasBrian D Weiss, Pamela L Wolters, Scott R Plotkin, et al.
Molecular Pharmacology|June 9, 2019
Severe Hepatotoxicity of Mithramycin Therapy Caused by Altered Expression of Hepatocellular Bile TransportersTristan M Sissung, Phoebe A Huang, Ralph J Hauke, et al.
Sarcoma|November 16, 2017
SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath TumorsChristine S Higham, Seth M Steinberg, Eva Dombi, et al.
Pageof 21